interleukin-4 receptor alpha-lytic peptide

**Interleukin-4 receptor alpha-lytic peptide** is a synthetic hybrid peptide composed of two functional domains: one that binds selectively to the interleukin-4 receptor alpha (IL-4Rα), which is highly expressed on the surface of several human solid tumors, and a lytic peptide domain that induces cancer cell death by disrupting the cell membrane[1][3][5]. This molecularly targeted therapy selectively kills IL-4Rα-positive cancer cells while sparing normal cells. It has demonstrated potent antitumor activity in vitro and in vivo, including significant tumor regression in mouse xenograft models of biliary tract cancer, pancreatic cancer, and head and neck squamous cell carcinoma[1][2][3][4][5]. The peptide is not an antibody or small molecule, but a designed synthetic peptide, potentially allowing easier synthesis and lower cost compared to antibody-based therapeutics[1]. Synergistic cytotoxicity has been reported when used in combination with gemcitabine[1]. Primary indications studied are solid tumors with high IL-4Rα expression, notably biliary tract cancer, pancreatic cancer, and head and neck squamous cell carcinoma[1][2][3].

Other names

interleukin-4 receptor alpha-lytic hybrid peptideinterleukin4 receptor alpha-lytic hybrid peptideinterleukin 4 receptor alpha-lytic hybrid peptideIL-4Rα-lytic peptide